Oxaliplatin may leads to lower overall Survival compared with the same regimen including cisplatin (low certainty).
Oxaliplatin probably leads to higher tumour response compared with the same regimen including cisplatin (moderate certainty).
Oxaliplatin showed no clear difference in progression‐free survival compared with the same regimen including cisplatin (low certainty).
Oxaliplatin showed no clear difference in treatment‐related death compared with the same regimen including cisplatin (low certainty).
It is very uncertain whether oxaliplatin changes treatment discontinuation due to toxicity compared with the same regimen including cisplatin (very low certainty).
Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with best supportive care (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus oxaliplatin changes overall response rate compared with best supportive care (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus folinic acid (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus oxaliplatin changes overall response rate compared with 5‐fluorouracil plus folinic acid (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).